Avecho Biotechnology Limited
AVEFF
$0.0045
-$0.0129-74.14%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 2,937.50% | 2,988.76% | -30.99% | -32.70% | -92.79% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2,937.50% | 2,988.76% | -30.99% | -32.70% | -92.79% |
| Cost of Revenue | -8.60% | -6.44% | -19.35% | -21.41% | 185.59% |
| Gross Profit | 228.41% | 231.39% | -35.75% | -37.35% | -251.93% |
| SG&A Expenses | 26.42% | 29.35% | -34.03% | -35.66% | -37.21% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 29.13% | 32.17% | -4.61% | -6.95% | -31.90% |
| Operating Income | 31.20% | 29.60% | -0.96% | 1.53% | 17.46% |
| Income Before Tax | 27.68% | 25.99% | -0.86% | 1.62% | 17.08% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 27.68% | 25.99% | -0.86% | 1.62% | 17.08% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 27.68% | 25.99% | -0.86% | 1.62% | 17.08% |
| EBIT | 31.20% | 29.60% | -0.96% | 1.53% | 17.46% |
| EBITDA | 32.77% | 31.19% | -2.54% | -0.01% | 16.60% |
| EPS Basic | 50.00% | 50.00% | 50.00% | 50.00% | 33.33% |
| Normalized Basic EPS | 0.00% | 0.00% | 50.00% | 50.00% | 50.00% |
| EPS Diluted | 50.00% | 50.00% | 50.00% | 50.00% | 33.33% |
| Normalized Diluted EPS | 0.00% | 0.00% | 50.00% | 50.00% | 50.00% |
| Average Basic Shares Outstanding | 21.66% | 21.66% | 64.12% | 64.12% | 41.75% |
| Average Diluted Shares Outstanding | 21.66% | 21.66% | 64.12% | 64.12% | 41.75% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |